糖酸酶 (PGK) 1化调节发作和血脑屏障
Yuemei Luo1, Juan Yang1, Lijia Zhang1
1Department of Neurology, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Zunyi, Guizhou 563003, P.R. China.
Experimental animals
|May 31, 2023
概括
这项研究揭示了中酸激酶1 (PGK1) 糖化降低会影响血脑屏障的完整性. 在K15部位修改PGK1会影响活动,并提出新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 是一种常见的神经系统疾病,其特点是经常性发作.
- 后翻译性修改 (PTMs),如化,在生理和病理过程中调节蛋白质功能.
- 糖酸酶1 (PGK1) 是一种糖溶性酶,也在血管生成,自和DNA修复中发挥作用.
研究的目的:
- 为了研究中糖酸激酶1 (PGK1) 糖化作用.
- 探索PGK1化在K15部位对病原和血脑屏障完整性的影响.
主要方法:
- 利用一种-皮洛卡尔诱导的急性的小鼠模型.
- 通过免疫沉和西部涂抹评估了PGK1化.
- 测量了血管静止素,血管内皮生长因子 (VEGF) 和S100β水平,使用西班牙血栓和ELISA.
- 分析行为变化和血脑屏障的完整性.
主要成果:
- 与对照组相比,性大鼠的海马体中PGK1化减少.
- 在K15部位的PGK1突变改变了PGK1化水平,并影响了的易感性.
- 在K15的PGK1化影响了血管静止素和VEGF的表达,影响了S100β水平和血脑屏障的完整性.
结论:
- 特别是在K15部位的PGK1化在中起作用.
- 在PGK1化中的变化可能会通过血管静止素/VEGF通路影响血脑屏障的完整性.
- 向PGK1化是一种潜在的新型治疗策略.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
Epilepsy and Seizures: Overview
230
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
230
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
Antiepileptic Drugs: Glutamate Antagonists
435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K


